#	Pagina
attuale pagina	/open-h2020/projects/217757/results.html

Report

Teaser, summary, work performed and final results

Periodic Reporting for period 1 - UNLEASHAD (Unleashing the curative potential of cancer immunotherapy)

Teaser

Summary

TILT Biotherapeutics is developing a breakthrough oncolytic immunotherapy treatment for cancer. There are 9.6 million people dying from cancer each year and the incidence is growing rapidly. Advanced solid tumors are currently incurable and limited treatment options are available. Preclinical data on TILT technology suggests curative potential in numerous preclinical studies in aggressive cancer models, providing a strong rational for entering te Phase I clinical trial. New immunotherapies for cancer are more widely available in America than in Europe partly because clinical research concentration in the U.S. Cancer patients also in Europe are in the increasing need of new treatment options.
The objective of this project, initiated in July 2018, is to generate clinical data for the companyâ€™s lead product, TILT-123, given with a checkpoint inhibitor in advanced solid tumors. From the business perspective, this project allows the company to mature into a stage from where its further development could be privately funded and supported by a pharmaceutical company. TILT Biotherapeutics is investing into further development of its pipeline projects, creating more employment and business locally in Finland and Europe, and bringing an innovative treatment option with curative potential to the reach of European cancer patients.

Work performed

Since the beginning of the reporting period, clinical trial preparations have been carried out by initiating the regulatory interactions with the European Medicines Agency (EMA), by producing the pilot and clinical grade batches of the drug product (TILT-123), by setting up immunomonitoring studies, and by building the commercial case with increasing company visibility among pharma and private investors. Importantly, a regulatory approval for the first-in-man clinical trial was obtained. In addition, a clinical collaboration with a big pharma for the study of TILT-123 with a checkpoint inhibitor was initiated.

Final results

This SME Phase 2 project enables TILT Biotherapeutics to create more employment and business locally in Finland and Europe as well as to bring a new treatment option with curative potential to the reach of European cancer patients.